Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges
出版年份 2021 全文链接
标题
Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges
作者
关键词
-
出版物
Future Oncology
Volume -, Issue -, Pages -
出版商
Future Medicine Ltd
发表日期
2021-08-02
DOI
10.2217/fon-2020-1255
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Clinical outcomes and radiation pneumonitis after concurrent EGFR ‐tyrosine kinase inhibitors and radiotherapy for unresectable stage III non‐small cell lung cancer
- (2021) Kunpeng Xu et al. Thoracic Cancer
- Why Not Adore ADAURA?—The Trial We Need vs the Trial We Got
- (2021) Howard (Jack) West et al. JAMA Oncology
- For a better adjuvant strategy for resected lung cancer—lessons from treatment failure patterns of the ADJUVANT trial (CTONG 1104)
- (2020) Kenichi Suda Translational Lung Cancer Research
- CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial.
- (2020) Yi-Long Wu et al. JOURNAL OF CLINICAL ONCOLOGY
- ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.
- (2020) Jacob Sands et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma
- (2020) Peter J. Kneuertz et al. LUNG CANCER
- New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1)
- (2020) Alessandro Russo et al. Current Oncology Reports
- Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors
- (2020) Heikki Joensuu et al. JAMA Oncology
- Comparative Efficacy of Targeted Therapies in Patients with Non-Small Cell Lung Cancer: A Network Meta-Analysis of Clinical Trials
- (2020) Tung Hoang et al. Journal of Clinical Medicine
- The Effect of Advances in Lung-Cancer Treatment on Population Mortality
- (2020) Nadia Howlader et al. NEW ENGLAND JOURNAL OF MEDICINE
- LBA3_PR An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Primary end-point analysis of LungART (IFCT-0503, UK NCRI, SAKK) NCT00410683
- (2020) C. Le Pechoux et al. ANNALS OF ONCOLOGY
- Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer
- (2020) Yi-Long Wu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lessons From ADAURA on Adjuvant Cancer Drug Trials: Evidence, Ethics, and Economics
- (2020) Bishal Gyawali et al. JOURNAL OF CLINICAL ONCOLOGY
- ADAURA : Mature Enough for Publication, Not for Prime Time
- (2020) Alfredo Addeo et al. ONCOLOGIST
- Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades
- (2019) Tao Lu et al. Cancer Management and Research
- Combination of stereotactic radiotherapy and targeted therapy: patterns-of-care survey in German-speaking countries
- (2019) S. G. C. Kroeze et al. STRAHLENTHERAPIE UND ONKOLOGIE
- Concurrent EGFR‐TKI and Thoracic Radiotherapy as First‐Line Treatment for Stage IV Non‐Small Cell Lung Cancer Harboring EGFR Active Mutations
- (2019) LinPeng Zheng et al. ONCOLOGIST
- Editorial
- (2019) C Kim et al. ANNALS OF ONCOLOGY
- Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non–Small-Cell Lung Cancer
- (2019) Jeffrey D. Bradley et al. JOURNAL OF CLINICAL ONCOLOGY
- Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario
- (2018) Alfredo Addeo et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- The ASCENT trial: A phase II study of neoadjuvant afatinib, chemoradiation and surgery for stage III EGFR mutation-positive NSCLC.
- (2018) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
- (2018) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2)EGFRMutation‐Positive Non‐Small Cell Lung Cancer: A Prospective, Single‐Arm, Phase II Study
- (2018) Liwen Xiong et al. ONCOLOGIST
- Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial
- (2018) Dongsheng Yue et al. Lancet Respiratory Medicine
- Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
- (2018) J. Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer
- (2018) Nathan A. Pennell et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Study of Preoperative Chemoradiotherapy ± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Non–Small Cell Lung Cancer: NRG Oncology RTOG 0839
- (2017) Martin J. Edelman et al. Journal of Thoracic Oncology
- Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial
- (2017) Heather A Wakelee et al. LANCET ONCOLOGY
- Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs
- (2017) Choong-kun Lee et al. LUNG CANCER
- Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer
- (2017) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Survival improvement in patients with non–small cell lung cancer between 1983 and 2012: Analysis of the Surveillance, Epidemiology, and End Results database
- (2017) Shuncong Wang et al. TUMOR BIOLOGY
- Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling
- (2017) Aadel A. Chaudhuri et al. Cancer Discovery
- Targeted therapy combined with radiotherapy in non-small-cell lung cancer: a review of the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society)
- (2016) F. Couñago et al. Clinical & Translational Oncology
- The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
- (2016) Peter Goldstraw et al. Journal of Thoracic Oncology
- Feasibility, tolerability, and efficacy of the concurrent addition of erlotinib to thoracic radiotherapy in locally advanced unresectable non-small-cell lung cancer: a Phase II trial
- (2016) Enrique Martínez et al. OncoTargets and Therapy
- Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
- (2016) Jacob J. Chabon et al. Nature Communications
- ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer
- (2015) R. Govindan et al. CLINICAL CANCER RESEARCH
- Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial
- (2015) Karen Kelly et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status
- (2015) Wenzhao Zhong et al. Journal of Hematology & Oncology
- Synergistic effects of crizotinib and radiotherapy in experimental EML4–ALK fusion positive lung cancer
- (2015) Ying Dai et al. RADIOTHERAPY AND ONCOLOGY
- Tumour tissue sampling for lung cancer management in the era of personalised therapy: what is good enough for molecular testing?
- (2014) L. Kim et al. EUROPEAN RESPIRATORY JOURNAL
- Radiation Pneumonitis in Patients with Non–Small-Cell Lung Cancer Treated with Erlotinib Concurrent with Thoracic Radiotherapy
- (2014) Hongqing Zhuang et al. Journal of Thoracic Oncology
- Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study
- (2013) Glenwood D. Goss et al. JOURNAL OF CLINICAL ONCOLOGY
- Additional weekly Cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: Efficacy and safety outcomes of a randomized, multi-center phase II study investigating
- (2013) Michel M. van den Heuvel et al. RADIOTHERAPY AND ONCOLOGY
- The different radiosensitivity when combining erlotinib with radiation at different administration schedules might be related to activity variations in c-MET-PI3K-AKT signal transduction
- (2013) Hong-qing Zhuang et al. OncoTargets and Therapy
- Erlotinib and Concurrent Chemoradiation in Pretreated NSCLC Patients: Radiobiological Basis and Clinical Results
- (2013) Sara Ramella et al. Biomed Research International
- Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG 0402)
- (2012) S. Niho et al. ANNALS OF ONCOLOGY
- Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design
- (2011) J. E. Chaft et al. CLINICAL CANCER RESEARCH
- Randomized Phase II Study of Pemetrexed, Carboplatin, and Thoracic Radiation With or Without Cetuximab in Patients With Locally Advanced Unresectable Non–Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 30407
- (2011) Ramaswamy Govindan et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Cetuximab in Combination With Chemoradiation in Patients With Stage IIIA/B Non–Small-Cell Lung Cancer: RTOG 0324
- (2011) George R. Blumenschein et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib in Combination With Irradiation With or Without Cisplatin in Patients With Inoperable Stage III Non–Small Cell Lung Cancer: A Phase I Trial
- (2010) Sacha Rothschild et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- A Phase I Study of Gefitinib with Concurrent Dose-Escalated Weekly Docetaxel and Conformal Three-Dimensional Thoracic Radiation Followed by Consolidative Docetaxel and Maintenance Gefitinib for Patients with Stage III Non-small Cell Lung Cancer
- (2010) Brian Center et al. Journal of Thoracic Oncology
- Chemoradiotherapy and Gefitinib in Stage III Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor and KRAS Mutation Analysis: Cancer and Leukemia Group B (CALEB) 30106, a CALGB-Stratified Phase II Trial
- (2010) Neal Ready et al. Journal of Thoracic Oncology
- Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor
- (2010) Isamu Okamoto et al. LUNG CANCER
- Long-Term Results of the International Adjuvant Lung Cancer Trial Evaluating Adjuvant Cisplatin-Based Chemotherapy in Resected Lung Cancer
- (2009) Rodrigo Arriagada et al. JOURNAL OF CLINICAL ONCOLOGY
- Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
- (2008) Jean-Pierre Pignon et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non–Small-Cell Lung Cancer: SWOG S0023
- (2008) Karen Kelly et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of Erlotinib-Based Multimodality Therapy for Inoperable Stage III Non-small Cell Lung Cancer
- (2008) Nicholas W. Choong et al. Journal of Thoracic Oncology
- Induction Chemotherapy with Carboplatin, Irinotecan, and Paclitaxel Followed by High Dose Three-Dimension Conformal Thoracic Radiotherapy (74 Gy) with Concurrent Carboplatin, Paclitaxel, and Gefitinib in Unresectable Stage IIIA and Stage IIIB Non-small Cell Lung Cancer
- (2008) Thomas E. Stinchcombe et al. Journal of Thoracic Oncology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now